EP2 logo

ViroGates DB:EP2 Stock Report

Last Price

€0.92

Market Cap

€5.7m

7D

16.7%

1Y

n/a

Updated

29 Oct, 2024

Data

Company Financials

EP2 Stock Overview

An in vitro diagnostics company, develops and markets prognostic products for the healthcare sector.

EP2 fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health3/6
Dividends0/6

ViroGates A/S Competitors

Price History & Performance

Summary of all time highs, changes and price drops for ViroGates
Historical stock prices
Current Share PriceDKK 0.92
52 Week HighDKK 0.92
52 Week LowDKK 0.78
Beta0.94
11 Month Changen/a
3 Month Changen/a
1 Year Changen/a
33 Year Changen/a
5 Year Changen/a
Change since IPO10.02%

Recent News & Updates

No updates

Recent updates

No updates

Shareholder Returns

EP2DE Medical EquipmentDE Market
7D16.7%-3.7%-0.1%
1Yn/a2.6%18.1%

Return vs Industry: Insufficient data to determine how EP2 performed against the German Medical Equipment industry.

Return vs Market: Insufficient data to determine how EP2 performed against the German Market.

Price Volatility

Is EP2's price volatile compared to industry and market?
EP2 volatility
EP2 Average Weekly Movementn/a
Medical Equipment Industry Average Movement5.2%
Market Average Movement4.9%
10% most volatile stocks in DE Market11.0%
10% least volatile stocks in DE Market2.5%

Stable Share Price: EP2's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: Insufficient data to determine EP2's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
200010Jakob Knudsenwww.virogates.com

ViroGates A/S, an in vitro diagnostics company, develops and markets prognostic products for the healthcare sector. It offers suPARnostic, a proprietary biomarker used in hospital emergency services to support the clinical decision on hospitalization or discharge of acute patients and to identify high-risk sepsis patients at an early stage, as well as used for the prognosis of lifestyle-related diseases, such as cardiovascular disease, type 2 diabetes, and cancer; and for the assessment of longevity and biological age in a non-hospital setting. The company’ products icludes suPARnostic TurbiLatex, a latex particle-enhanced turbidimetric immunoassay that quantitatively determines the soluble urokinase plasminogen activator receptor (suPAR) level in human K2-EDTA- or lithium heparin plasma samples; suPARnostic ELISA that provides fully quantitative results; suPARnostic Quick Triage kit, which is used in the point of care situation for early warning and patient triaging that will allow clinicians and nurses to obtain a fast patient prognosis for patient disease severity, progression and outcome; and suPARnostic POC+, a point-of-care finger prick test that detects the level of suPAR in the blood.

ViroGates A/S Fundamentals Summary

How do ViroGates's earnings and revenue compare to its market cap?
EP2 fundamental statistics
Market cap€5.66m
Earnings (TTM)-€1.76m
Revenue (TTM)€925.30k

6.1x

P/S Ratio

-3.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
EP2 income statement (TTM)
RevenueDKK 6.90m
Cost of RevenueDKK 1.62m
Gross ProfitDKK 5.28m
Other ExpensesDKK 18.42m
Earnings-DKK 13.13m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

Nov 07, 2024

Earnings per share (EPS)-2.04
Gross Margin76.53%
Net Profit Margin-190.25%
Debt/Equity Ratio56.9%

How did EP2 perform over the long term?

See historical performance and comparison